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Patients with failure of infarct-related artery recanalization
after thrombolytic therapy have a poor clinical outcome.
These patients have been considered for rescue angioplasty
90 min after thrombolytic therapy at the time of emergency
catheterization in the course of five Thrombolysis and
Angioplasty in Myocardial Infarction (TAMI) trials. The
outcome of 776 patients with patent infarct-related vessels
after emergency catheterization was analyzed-607 with
thrombolysis-mediated patency of the infarct-related vessel
and 169 with patency achieved by angioplasty.
Baseline characteristics of the thrombolysis and angio-
plasty patency groups were similar except for a higher
acute left ventricular ejection fraction (51.3% versus
48.2 %) in the thrombolysis group (p =0.003). Seven to 10
day left ventricular ejection fraction was higher (52.3%
versus 48.1 %), infarct zone functional recovery was greater
(0.44 versus 0.21 standard deviation/chord, or 18% versus
Although intravenous thrombolytic therapy unequivocally
improves survival and left ventricular function in patients
with evolving myocardial infarction, at least 25% of infarct-
related arteries fail to recanalize 90 to 120 min after treat-
ment. It is clear that patients with failure of infarct-related
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7%, P = 0.001) and reoccIusion was less (11 % versus 21 %)
in the thrombolysis compared with the angioplasty group.
Despite these differences, angioplasty patency was asso-
ciated with the same low in-hospital mortality rate (5.9%
versus 4.6%) and long-term mortality rate (3% versus 2%)
as thrombolysis patency. ReoccIusion adversely affected the
mortality rate and ventricular functional recovery. Techni-
cal failure of rescue angioplasty was associated with a much
higher mortality rate than was technical success (39.1 %
versus 5.9%). Thrombolysis patency was preferable to
angioplasty patency after thrombolytic therapy in acute
myocardial infarction, but both were associated with the
same low in-hospital and long-term mortality rates, sug-
gesting that rescue angioplasty is beneficial in some patients
with failure of infarct-related artery recanalization after
thrombolytic therapy.
(J Am Coli CardioI1990;16:770-8)
artery recanalization after pharmacologic intervention have
an especially poor prognosis (1). The mechanical strategy of
using emergency coronary angioplasty as a fallback means of
achieving infarct-related vessel patency has been termed
'"salvage" or '"rescue" angioplasty (2-5).
Initial data from several small pilot studies (2,4) suggest
that patency can be achieved in a high proportion of patients
and that left ventricular function and clinical outcomes may
be improved by rescue coronary angioplasty. However, the
approach requires emergency cardiac catheterization, a pol-
icy that represents a strain on health care resources because
only 12% of hospitals in the United States are equipped with
a cardiac catheterization laboratory and regularly perform
coronary angioplasty (6). Furthermore, the incidence of
bleeding complications is clearly increased by performing
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cardiac catheterization in the setting ofongoing thrombolytic
therapy (7-10). An additional concern relates to the potential
that rescue angioplasty may actually induce intraluminal
trauma of the infarct-related vessel, increasing the likelihood
of reocclusion and complications. In comparing these poten-
tial negative effects with those associated with not interven-
ing mechanically, allowing an additional 10% to 15% of
patients to develop late (>24 h) arterial patency (Thrombol-
ysis in Myocardial Infarction [TIM!] [11] flow grade 2:2), the
balance is uncertain.
Since the inception of the Thrombolysis and Angioplasty
in Myocardial Infarction (TAMl) trials (7,12-15), patients
whose infarct-related artery failed to recanalize have been
considered for rescue angioplasty. This study was under-
taken to provide a detailed assessment of the in-hospital and
long-term outcome of rescue angioplasty, the factors that
correlate with benefit and the potential risks associated with
this strategy.
Methods
Patient selection. The criteria for patient selection in the
TAMI trials have been reported previously (7.12-15). Pa-
tients were considered for inclusion if they had <4 h of chest
pain or severe pain with a duration of 4 to 6 hand 2: I mm
electrocardiographic ST segment elevation in two contigu-
ous leads. Exclusion criteria included age>75 years, recent
trauma, surgery or stroke. predisposition to hemorrhage.
prolonged cardiopulmonary resuscitation, prior coronary
bypass surgery. cardiogenic shock and previous transmural
infarction in the same area. Informed consent was obtained
from all patients before participation.
Intervention protocol. Thrombolytic therapy in a total of
847 patients was followed by emergency cardiac catheteriza-
tion to establish infarct-related artery patency status 90 min
after initiation of therapy. Patients with an occluded (TIMI
flow grade .:s I) infarct-related vessel and suitable anatomy
(192 of 235 patients) underwent angioplasty to restore vessel
patency. Patients were excluded from angioplasty (n = 43)
when there was a left main artery stenosis 2:50% and the
target lesion was in the left circumflex or left anterior
descending artery, when there was diffuse severe multives-
sel disease deemed unsuitable for angioplasty and when
there was uncertainty regarding the infarct-related vessel. In
the first 386 patients, those with suitable anatomy and patent
(TIMI flow grade 2:2) infarct-related vessels were random-
ized to immediate or delayed (7 to 10 days) angioplasty. In
subsequent patients with patent infarct-related vessels. an-
gioplasty was deferred unless there was evidence of ongoing
ischemia as evidenced by severe pain. marked ST segment
elevation or angiographic evidence of collateral flow to the
infarct-related vessel.
All patients received heparin (5.000 U at vascular access
and an additional 5,000 U if angioplasty was performed),
Table l. Thrombolytic Regimens in 847 Patients*
No. of
Patients Agents Total Dose Method of Administration
176 rt-PA 150 mg 60 mg 1st h. 20 mglh x 2.
10 mglh x 5
208 rt-PA 150 mg ) mglkg 1st h up to 90 mg.
remainder over 5 h
143 rt-PA 25 mg to I mglkg Up to 90 mg over I h
Urokinase 0.5 to 2 million U Over I h
172 rt-PA 1.5 mglkg I mglkg 1st h up to 90 mg
0.5 mg/kg over next 3 h up
to 45 mg
50 rt-PA 100 mg I mg/kg up to 80 mg.
remainder over 3 h
Iloprost 0.5 mglkg per min 1st 5
min. then 1-2 mglkg per
min for 48 h
98 Urokinase 3 million U Over 30 to 45 min
'For details. refer to references 7 and 12 to 15. rt-PA = recombinant
tissue-type plasminogen activator.
except for 172 patients who were randomized to receive
10.000 U of heparin at the onset of thrombolytic therapy or
90 min later. Heparin (300 to 1,000 U/h) was infused after
termination of the interventional procedure and adjusted to
keep the partial thromboplastin time 1.5 to 2.5 times the
control level for 2:24 h. All patients also received aspirin
(325 mg) emergently and daily, and diltiazem (30 to 60 mg,
four times per day). During the first 24 h, all patients
received lidocaine and intravenous nitroglycerin unless
these agents were contraindicated.
Emergency repeat cardiac catheterization was performed
for recurrent ischemia defined as >20 min of angina unre-
sponsive to nitroglycerin, associated with ST segment ele-
vation. Repeat thrombolytic therapy, angioplasty or coro-
nary bypass surgery was performed at the discretion of the
cardiologist. Patients underwent follow-up cardiac catheter-
ization after 7 to 10 days to assess vessel patency and
ventricular function. Subsequent angioplasty or coronary
bypass surgery was performed as clinically indicated. In-
formed consent was obtained from all patients before they
entered the trials. The institutional committee on human
research at each center approved the study protocols.
Thrombolytic regimens (Table I). The agents used were
recombinant tissue-type plasminogen activator (rt-PAI alone
(n = 556), a combination of rt-PA and urokinase (n = 143).
a combination of rt-PA and a prostacyclin analogue (110-
prost) (n = 50) and urokinase alone (n = 98). Intracoronary
thrombolytic therapy could be given in patients who met the
following criteria: II an angiographically visible filling defect
suggesting the presence of residual thrombus after angio-
plasty: 2) marked diminution of flow in the infarct-related
artery. with imminent reclosure or abrupt closure of the
artery after angioplasty: or 3) evidence of distal embolization
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Figure 1. Outcome of thrombolysis
(Chemical) and angioplasty at emer-
gency catheterization in 847 patients.
*Chemical patency group (607 patients);
**mechanical patency group (169 pa-
tients).
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as recognized by angiographic vessel pruning. Agents used
in the various trials included intracoronary rt-PA (30 mg over
IS to 30 min) and intracoronary urokinase (50,000 to
60,000 U bolus injection and 4,000 to 6,000 U/min for 30 min
up to 2 h).
Angiographic analysis. Left ventricular angiographic
analysis was performed at the angiographic core laboratory
at the University of Michigan, Ann Arbor, by a single
observer who was unaware of patient or treatment data.
Outlines of end-diastolic and end-systolic right anterior
oblique contrast ventriculograms were digitized and stored
on a digital radiographic computer (DPS 4100C, ADAC
Laboratories) for subsequent processing. Global ejection
fraction was determined by the area-length method and
regional wall motion by the center line chord method (16).
Wall motion abnormalities were described as the mean value
of chords in the most hypokinetic 50% of the infarct-related
artery territory and expressed in standard deviations per
chord (SD/chord). Studies marred by premature ventricular
contractions or inadequate opacification were excluded from
the analysis.
Data analysis. Drug success or failure was defined, re-
spectively, as TIM! flow grade 22 or ~ I on the 90 min
angiogram. Angioplasty success or failure was similarly
defined at completion of the emergency catheterization. The
frequency of the various vessel treatment outcomes in the
total patient group of 847 patients are shown in Figure I. The
comparison of baseline data and outcome of the 607 patients
demonstrating thrombolysis-mediated infarct-related vessel
patency at 90 min and at completion of the emergency
catheterization with that of the 169 patients whose infarct-
related artery was not patent after thrombolytic therapy but
who underwent successful rescue angioplasty forms the
basis of this report. To determine the potential of a strategy
free ofreocclusion, the outcome of patients whose vessel did
or did not reocclude was compared. The effect of infarct-
related artery and technical success on outcome after rescue
angioplasty is described.
Statistics. Values are expressed as mean values ± lSD,
Categoric variables were tested with the Mantel-Haenszel
test, which adjusts for the differences between protocols.
Continuous variables were tested using linear regression
analysis, which adjusts for the difference between protocols
and baseline values.
Follow-up. Follow-up information in 662 (95%) of the
first 699 patients was obtained by mailed questionnaire or
telephone contact regarding vital status, recurrent myocar-
dial infarction and subsequent hospitalizations, angioplasty
and coronary bypass surgery. The median follow-up time
was 20 months (range 1.1 to 39.7). Follow-up event rates
were calculated using the Kaplan-Meier method.
Table 2. Baseline Characteristics of 776 Patients With Successful
Thrombolysis or Angioplasty Patency*
Thrombolysis Angioplasty
Patency Patency
No. of patients 607 169
Mean age:! SO (yr) 56:! 10 55 :! 9
Male gender (% men) 488 (80%) 135 (80%)
Risk factor (% I
Hypertension 41 40
Diabetes mellitus 15 12
Hyperlipidemia 13 10
Peripheral vascular disease 6 4
Cerebral vascular disease 3
Family history 45 45
History of smoking 64 66
Previous myocardial infarction 13 10
Infarct-related coronary artery (%)
Left main 1«1%) 0(0%)
LAD 244 (41%) 64 (38%)
Left circumflex 72 (12%) 23 (14%)
Right 280 (47%) 81 (48%)
Graft 3 (1%) 1 (1%)
Multivessel disease 284 (47%) 67 (40%)
Mean LVEF (%) 51 ± 11 48 ± 10
p = 0.003
Mean IZ RWM (SO/chord) -2.5 ± 1.1 -2.9 ± 0.9
p < 0.003
*There were no significant differences in baseline characteristics except
for left ventricular function. IZ = infarct zone: LAD = left anterior descend-
ing: LVEF = left ventricular ejection fraction: RWM = regional wall motion.
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Thrombolysis Angioplasty
Patency Patency
No. of patients 607 169
Death 2814.6(jf) 10 (5.9(jf)
Reocclusion 64 111'k) 36 (21'k)
Coronary bypass surgery
None 474 178'k) 156 (92'k)
Emergency 33 (5(jf) 3 (2'lr)
Urgent 3916(jf1 6 (4'lr1
Elective 61 110(jf) 4 (2'lr1
Angioplasty
Emergency 59 (10'lr) 10 (6'IC)
Elective 173 (31(jf) 12 (8'lr1
Paired studies of cardiac function
6 LVEF (7 days versus baseline) 0.99 :!: 9 -n.06 :!: 8
(% units)
6 IZ RWM (7 days versus 0.44 :!: 1.07 (1.21 :!: n.90
baseline) (SO/chord)
p Value
0.364
<0.001
n.onl
0.125
0.001
0.008
0.001
6 - change in: other abbreviations as in Table 2.
Figure 2. Infarct zone regional wall motion in the thrombolysis
(Chemical) and angioplasty (Mechanical) patency groups.
with angioplasty patency (0.44 versus 0.21 SO/chord. p =
0.(01) (Fig. 2).
Impact of rescue angioplasty failure. The mortality rate in
patients with failed rescue angioplasty was significantly
higher than that in patients in whom the procedure was
successful (39.1% versus 5.9%) (Fig. 3), despite comparable
baseline characteristics. Seven of the nine patients who died
in the failed angioplasty group developed cardiogenic shock.
two before transfer to the catheterization laboratory and five
while in the catheterization laboratory. The site of coronary
occlusion was in the proximal left anterior descending cor-
onary artery in seven patients. the left main coronary artery
in one patient and the mid-right coronary artery in one
patient.
Results
Baseline characteristics (Table 2). No differences were
observed in patients with thrombolysis patency (n = 607)
versus angioplasty patency (n = 169) with regard to age.
gender, standard risk factors for coronary artery disease,
prior myocardial infarction, infarct-related vessel or extent
of coronary artery disease. Both global left ventricular
ejection fraction and regional wall motion were significantly
worse at baseline study in the angioplasty patency group.
In-hospital outcome (Table 3). The in-hospital mortality
rate was the same in the thrombolysis and angioplasty
groups. Reocelusion occurred significantly more frequently
(p < 0.(01) in the angioplasty patency group. The reocclu-
sion rate in the angioplasty patency group was 29% (n = 108)
in those treated with rt-PA alone. 12% (n = 26) in those
treated with urokinase alone and 4% (n = 21) in those treated
with the combination of rt-PA and urokinase (p = 0.019).
Reocclusion in the combined groups of thrombolysis and
angioplasty patency was associated with a higher mortality
rate (9% versus 4%, p = 0.013), deterioration in left ventric-
ular ejection fraction (-2% units versus +I% unit. p = 0.02)
and less infarct zone regional wall motion recovery (0.11
versus 0.43 SO/chord, p = 0.005) compared with no reoc-
elusion. The use of subsequent coronary bypass surgery and
elective angioplasty was significantly higher in the thrombol-
ysis patency group. The left ventricular ejection fraction
increased by 1% unit in the patients with thrombolysis
patency and exhibited no improvement (-0.06% unit) in the
patients with angioplasty patency (p = 0.008). Regional wall
motion recovery in the infarct zone was significantly greater
in the patients with thrombolysis patency than in patients
-2
-3 -2.87
-4 ~ P < 0.012
P < 0.001
0.44
0.21
Patency
!li! Chemical
D Mechanical
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Table 5. Long-Term Event Rates in Hospital Survivors
(median 20 mo.)
No. of patients
Death
Cardiovascular death
Nonfatal MI
Death or MI
Coronary artery bypass surgery
Coronary angioplasty
Cardiac hospitalization
Any hospitalization
Technical
Failure
n=23
Technical
Success
n = 169
Rescue
Angioplasty
n =192
50
40 39.1')\
~
30.~
~
0 20::E
9.9'10
10
Figure 3. Effect of rescue angioplasty technical outcome on the
mortality rate in 192 patients.
MI = myocardial infarction.
Effect of infarct-related artery on rescue angioplasty (Table
4). The complications and outcome of rescue angioplasty of
the right and left anterior descending coronary arteries were
compared. Although the final acute catheterization technical
success rates were similar in the two groups, right coronary
artery rescue angioplasty was associated with more frequent
atrioventricular block, ventricular fibrillation, severe brady-
cardia, abrupt in-laboratory closure and transient hypoten-
sion. Sustained hypotension was almost as frequent in the
right coronary artery group, although intraaortic balloon
pumping was utilized more frequently in the left anterior
descending artery group. Despite considerably better base-
line and 7 day global left ventricular function in the right
coronary than in the left anterior descending artery group,
the mortality rates were similar.
Long-term follow-up (Table 5). There was no difference
between the patients discharged from the hospital with
thrombolysis patency (n = 473) and angioplasty patency (n
= 119) with regard to subsequent death, cardiovascular
death, nonfatal myocardial infarction, use of coronary by-
pass surgery or angioplasty or subsequent hospitalization.
Patients with unsuccessful rescue angioplasty (n =23) or no
rescue angioplasty (n =43) (Table 6). Reasons why rescue
angioplasty was not attempted in some patients included
spontaneous opening after the 90 min angiogram, distal
vessel occlusion with a small amount of myocardium at risk
and unsuitable coronary anatomy. Patients with unsuccess-
ful rescue angioplasty had a worse baseline global left
ventricular ejection fraction and a higher proportion of left
Table 6. Baseline Characteristics and Outcome of Patients
With Unsuccessful Thrombolysis and Either Failed or No
Angioplasty (PTCA)
Table 4. Effect of Infarct-Related Coronary Artery on Outcome of
Unsuccessful
PICA No PICA
Rescue Angioplasty in 165 Patients
No. of patients 23 43Coronary Artery
Mean age ± SO (yr) 56 ± 8 58 ± 10
Left Anterior Male gender (% men) 18 (78%) 35 (81%)
Right Descending Infarct-related coronary artery
No. of patients 91 74 (% of patients)
Intraprocedural events Left main 1(4%) 0
Mobitz 2, 3rd degree AV block 10 (12%) I (1%) LAD 10 (43%) 8 (19%)
Ventricular fibrillation 13 (16%) 6 (9%) Left circumflex 2 (9%) 9 (21%)
Severe bradycardia 21 (26%) 7 (10%) Right 10 (43%) 24 (56%)
Abrupt closure 9 (11%) 3 (4%) Graft 0 2 (5%)
Transient hypotension 24 (29%) II (16%) Mean LVEF 47.6 ± 17 50 ± 12
Hypotension> I h 10 (12%) 11 (16%) (n = 16) (n = 33)
Intraaortic balloon pumping 5 (6%) 16 (23%) Death 9 (39%) 3 (7%)
Technical success 81 (89%) 64 (87%)
0.4 ± 16.7 -1.1 ± 8.4Reocclusion 25/81 (31%) 11/64 (17%) /l LVEF (% units)
Mean baseline LVEF (%) 53.6 ± 9 40.9 ± 10 (n = 8) (n = 24)
Mean 7 day LVEF (%) 52.9 ± 9 43.9 ± 12 /lIZ RWM (SO/chord) 0.03 ± 1.03 0.39 ± 1.14
In-hospital death 8 (9%) 8 (11%) (n = 8) (n = 22)
AV = atrioventricular: other abbreviations in Table 2. Abbreviations as in Table 2.
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anterior descending infarct-related arteries than did patients
with no rescue angioplasty.
Discussion
Successful thrombolysis versus rescue coronary angio-
plasty. The most important finding in this study was that
coronary artery patency after thrombolytic therapy for acute
myocardial infarction was preferable to patency achieved
with angioplasty, with a greater left ventricular ejection
fraction and less infarct zone hypokinesia both initially and
at day 7 and half the rate of reocclusion. Another key
observation was that despite the worse ventricular function
outcome and higher rate of reocclusion in the angioplasty
patency group, the mortality rate was as low as that in the
thrombolysis patency group. The use of coronary bypass
surgery and elective angioplasty during the initial hospital-
ization was significantly less frequent in the angioplasty
patency group. The use of subsequent emergency angio-
plasty during the initial hospitalization was the same in both
groups. These results demonstrate the need for the develop-
ment of more effective means of opening coronary arteries
refractory to current pharmacologic approaches.
Mortality. Previous studies (17,18) have shown a re-
duced mortality rate in acute myocardial infarction when the
infarct-related artery is successfully recanalized compared
with when it is not. In the present study, the same low
mortality rate was seen whether patency was achieved with
thrombolysis alone or required rescue angioplasty. This
occurred despite worse baseline left ventricular function and
worse regional functional recovery, suggesting that the effect
is related in part to factors other than myocardial salvage.
This observation confirms previous studies (17,18) that have
also shown improved survival in trials comparing reperfu-
sion with conservative therapy with little or no improvement
in ventricular function. Explanations for the apparent im-
proved survival with an open infarct-related vessel in this
setting include improved healing with less remodeling, less
infarct expansion, improved electrical stability and availabil-
ity to provide collateral flow in case of future occlusion of
adjacent coronary arteries (19,20).
Left ventricular function. Infarct zone regional wall mo-
tion improved to a greater extent in the thrombolysis pa-
tency group compared with the angioplasty patency group
(18% versus 7%, p == 0.001). This difference may at least in
part be due to the longer time to reperfusion in the patients
with unsuccessful thrombolysis because rescue angioplasty
was delayed at least 90 min after the onset of therapy. That
no significant improvement in global left ventricular ejection
fraction was noted in either the thrombolysis or angioplasty
groups may be related to the relatively high baseline left
ventricular ejection fraction of the patients entered in these
trials.
Reocclusion. Patients treated with rescue angioplasty de-
veloped coronary reocclusion twice as frequently as patients
with thrombolysis patency (21% versus 11%). This finding
contrasts with the equal incidence of reocclusion in a sub-
group of patients with thrombolysis patency after rt-PA who
were randomized to emergency or delayed angioplasty (11%
versus 13%) (7) and suggests a fundamental difference in the
infarct-related vessel itself or its response to angioplasty in
the patient whose infarct-related artery fails to reperfuse
after thrombolytic therapy. Several explanations should be
considered for this observation. Recent pathologic studies
(21) have demonstrated that some arteries that fail to reper-
fuse have deeper, more extensive plaque fissures, a situation
that could lead to greater compromise of the vessel lumen
with further disruption by angioplasty. This problem could
be especially difficult if hemorrhage into the plaque is
increased as a result of the thrombolytic therapy. The delay
in reperfusion could lead to more extensive myonecrosis and
myocardial edema, especially if a hemorrhagic infarction
ensues, thus inhibiting coronary flow. The thrombus itself
could be different, particularly if enriched with platelets,
thus leading to resistance to fibrinolysis and enhanced reac-
tivity to mechanical trauma induced by angioplasty.
The risk of reocdusion after rescue angioplasty in this
study was profoundly different with alternative thrombolytic
regimens. Possible explanations for the lower rate of reoc-
clusion with urokinase (12%) or the combination of rt-PA
and urokinase (4%) compared with rt-PA alone (29%) in-
clude the more intense lytic state seen with nonselective
thrombolytic agents, their longer half-life and their produc-
tion of fibrin-split products that have a mild antiplatelet
effect. The lower rate of reocclusion after rescue angioplasty
with combined urokinase and rt-PA compared with uroki-
nase alone is intriguing and warrants further investigation. In
a small pilot study (22) of a I h infusion of rt-PA (50 mg) and
streptokinase (1.5 million U) in acute myocardial infarction,
the reocclusion rate was 8% overall and 12.5% after rescue
angioplasty (9).
Reduced need for revascularization procedures in the an·
gioplasty patency group. The decision to refer patients for
coronary bypass surgery was made at the discretion of the
cardiologist, not by predetermined specific criteria. Subse-
quent urgent and elective coronary bypass surgery was used
in 16% of the thrombolysis patency group compared with 6%
in the angioplasty patency group (p < 0.001), owing to the
correction of one major coronary lesion at the acute inter-
vention, thus making medical management more frequently
clinically appropriate. Subsequent elective angioplasty was
used in 31 % of the thrombolysis patency group compared
with only 8% of the angioplasty patency group (p < 0.001)
for the same reason. Although the incidence of reocclusion
was two times greater in the angioplasty patency group, the
use of emergency angioplasty was the same in the two
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groups because reocclusion frequently was not appreciated
clinically.
Long-term follow-up. Previous studies (23-25) of aggres-
sive reperfusion strategies in acute myocardial infarction
have reported the same extremely low postdischarge mor-
tality and reinfarction rates seen in this study. These rates
are considerably lower than those frequently reported for
patients treated with thrombolytic therapy alone (26) or for
patients with myocardial infarction in the era preceding
thrombolytic intervention (27). It is noteworthy that the
long-term benefit associated with successful rescue angio-
plasty was as good as that seen in the thrombolysis patency
group. A low long-term event rate has also been reported in
the TIMI trial (28) for patients managed according to a
conservative strategy in which cardiac catheterization and
angioplasty were performed only in patients with spontane-
ous or exercise-induced ischemia.
Comparison with previous studies. Small pilot studies
(2,4) have shown that rescue angioplasty after failed throm-
bolytic therapy can be accomplished with the same degree of
technical success (71% to 92%) as reported in this study.
Contrary to the findings in this study, Fung et al. (2)
demonstrated improved global ventricular function at 7 to 10
days (ejection fraction 53% to 59%, p < 0.002) and consid-
erably more return of infarct zone wall motion (from - 3.2 to
-1.9 SD/chord, p < 0.002) with rescue angioplasty after
failed thrombolysis. This difference is likely related to the
small numbers of patients studied, but may in part be
attributed to the use of streptokinase as the thrombolytic
agent in the study by Fung et al. (2). In line with the present
study, O'Connor et al. (29) reported no improvement in
global left ventricular ejection fraction with rescue angio-
plasty after failed streptokinase thrombolysis and half the
improvement in infarct zone regional wall motion in these
patients compared with patients with open vessels after
streptokinase who underwent emergency angioplasty (0.4
versus 0.8 SD/chord).
Factors affecting rescue angioplasty outcome. Reocclusion
was associated with a decrease in left ventricular ejection
fraction and less regional wall motion recovery in both the
thrombolysis and angioplasty patency groups. Reocclusion
was associated with a higher mortality rate in the thrombol-
ysis patency group. These data highlight the need for devel-
oping improved strategies to prevent reocclusion. Although
right coronary artery rescue angioplasty was associated with
more intraprocedural complications and considerably better
baseline and 7 day global left ventricular function than was
left anterior descending artery rescue angioplasty, the tech-
nical success and mortality rates were the same. Technical
failure of rescue angioplasty was associated with a much
higher mortality rate than was technical success (39.1 %
versus 5.9%). The invasive procedure with its attendant
stress, contrast-related hypotension and negative inotropic
effect, potential for guide wire perforation of the infarct-
related vessel, anemia due to access bleeding and other
complications could contribute to this apparent excess mor-
tality rate. The intraluminal trauma produced by rescue
angioplasty could predispose to rethrombosis Of prevent
delayed spontaneous thrombolysis. Another possibility is
that some unknown factor in patients with unsuccessful
thrombolysis may predispose to both death and nonresponse
to angioplasty. Eight of the nine patients who died after
unsuccessful rescue angioplasty had proximal coronary le-
sions and five had triple vessel disease, factors reported to
predict rescue angioplasty failure (30).
When should angioplasty patency be achieved? It is im-
portant to note that immediate angioplasty patency was not
studied in these trials because, by protocol, rescue angio-
plasty was delayed a minimum of 90 min after the onset of
thrombolysis. The outcome of rescue angioplasty might have
been better without this delay. Successful rescue angioplasty
if performed within 4 to 6 h was shown in this study to allow
for some regional myocardial recovery, albeit less than that
seen with successful thrombolysis. This is the current ac-
cepted maximal time to reperfusion that is thought to allow
for myocardial salvage. However, Guerci et al. (31) have
shown an improved response of left ventricular ejection
fraction to exercise in patients who were randomized to
angioplasty 3 days after infarction compared with those not
treated with angioplasty (+8% units versus +1.2% units, p <
0.02). Schroder et al. (32) reported a significant beneficial
effect of late reperfusion on regional and global left ventric-
ular function as determined by late peaking in the creatine
kinase MB isoenzyme time-activity curve in patients in their
study. If reperfusion confers survival benefit independent of
myocardial salvage (17,18), if late reperfusion produces
improvement in ventricular function (31,32) and if the
amount of myocardial salvage with rescue angioplasty is
small, it could be argued in some cases that rescue angio-
plasty would be better delayed a few days when the systemic
thrombolytic effect has cleared with its attendant risks of
bleeding and when the risk of acute rethrombosis is less.
Limitations of the study. The outcome of patients with
thrombolysis patency might have been even more favorable
than that of patients with angioplasty patency had the former
not undergone emergency cardiac catheterization to deter-
mine infarct-related vessel patency status. Only when a
suitable noninvasive method to assess reperfusion is used
can we really test this issue. Another limitation of the study
is that insights into the potential benefit or harm of rescue
angioplasty are tentative because this was not a randomized
study of rescue angioplasty. Until data from such a random-
ized trial become available, it remains possible that the
patients undergoing rescue angioplasty in the TAMI data
base may have had an equally positive if not improved
outcome without angioplasty. It is clear that even without
rescue angioplasty, nearly half of these patients will develop
late patency by ~24 h (33,34). The final limitation of this
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study is in the technology itself. When reperfusion was
successfully achieved, the outcome of patients with rescue
angioplasty was excellent. However, when the procedure
failed, the outcome may have been worse than expected.
Methods that improve the technical success rate, especially
as the mechanisms responsible for thrombolytic failure
become better understood, will substantially enhance the
beneficial effects of rescue angioplasty and minimize the
risks.
Conclusions. Vessel patency achieved with thrombolysis
is preferable to patency achieved with delayed emergency
angioplasty in patients with acute myocardial infarction
because of higher baseline and 7 day follow-up left ventric-
ular ejection fraction, less reocclusion and greater regional
wall motion recovery in the former group. Despite these
advantages of thrombolysis, successful rescue angioplasty is
associated with the same low in-hospital mortality rate and
low long-term morbidity and mortality. The use of predis-
charge coronary bypass surgery and coronary angioplasty
is lower in the angioplasty patency group. Because of
the absence of a suitable control group, these findings
support but do not prove the hypothesis that rescue angio-
plasty is beneficial in patients whose infarct-related artery
fails to reperfuse with thrombolysis. The outcome of the
procedure is critically dependent on the immediate success
rate, the risk of reocclusion and the type of thrombolytic
agent used.
These results suggest that as the technology of percuta-
neous coronary angioplasty improves our ability to establish
and maintain patency of the unstable coronary artery (for
example, stent, atherectomy. better balloon technology.
more potent platelet or thrombin inhibitors), the benefits
gained from rescue angioplasty should improve relative to
the risks.
We gratefully acknowledge the expert help of Nancy Halsey in the prepara-
tion of the manuscript.
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